Prelude Therapeutics Incorporated (PRLD) - Cekelan dhuwit saben saham

The level of liquid assets per share demonstrates Prelude Therapeutics (PRLD) dependence on external investments due to a lack of proprietary sales. 1.75 shows the current value of this metric. Stability is provided by a diversified set of tumor-fighting molecules, which mitigates investment risks. Patents for high-tech lymphatic system treatments guarantee long-term profit potential.
Rincian metrik komprehensif lan analitis Prelude Therapeutics Inc. (PRLD)

Cash per share determines the portion of liquid assets attributable to a single security by dividing the total cash balance by the number of shares outstanding. For Prelude Therapeutics (PRLD), this resource is critical for funding developments in precision oncology. By analyzing the cash per share metric, an investor assesses the business's internal margin of safety. High liquidity levels minimize the risks of underfunding clinical trials. This metric serves as a fundamental filter for the company's financial stability.